IMNM Stock Overview
Immunome, Inc., a biotechnology company, develops targeted cancer therapies.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Immunome, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.18 |
| 52 Week High | US$30.96 |
| 52 Week Low | US$4.44 |
| Beta | 1.66 |
| 1 Month Change | -28.65% |
| 3 Month Change | 27.26% |
| 1 Year Change | 223.54% |
| 3 Year Change | -41.92% |
| 5 Year Change | n/a |
| Change since IPO | 27.73% |
Recent News & Updates
Recent updates
Immunome: Why It Has Doubled Over The Last Month
Jan 18Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?
Mar 17
Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?
Nov 20Immunome GAAP EPS of -$0.74
Aug 05Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation
Aug 05Immunome gains 34% after preclinical data on COVID-19 antibody
Jun 30We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth
Feb 21Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth
Oct 02Immunome launches $27M private placement
Apr 26Do Institutions Own Immunome, Inc. (NASDAQ:IMNM) Shares?
Mar 12Read This Before Selling Immunome, Inc. (NASDAQ:IMNM) Shares
Jan 18Immunome EPS misses by $7.22
Nov 17Shareholder Returns
| IMNM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -18.3% | -4.7% | -3.7% |
| 1Y | 223.5% | -2.7% | 20.2% |
Return vs Industry: IMNM exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: IMNM exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| IMNM volatility | |
|---|---|
| IMNM Average Weekly Movement | 16.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IMNM's share price has been volatile over the past 3 months.
Volatility Over Time: IMNM's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 55 | Clay Siegall | immunome.com |
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company’s clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Immunome, Inc. Fundamentals Summary
| IMNM fundamental statistics | |
|---|---|
| Market cap | US$1.03b |
| Earnings (TTM) | -US$106.81m |
| Revenue (TTM) | US$14.02m |
73.2x
P/S Ratio-9.6x
P/E RatioIs IMNM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMNM income statement (TTM) | |
|---|---|
| Revenue | US$14.02m |
| Cost of Revenue | US$22.93m |
| Gross Profit | -US$8.91m |
| Other Expenses | US$97.90m |
| Earnings | -US$106.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.79 |
| Gross Margin | -63.54% |
| Net Profit Margin | -761.92% |
| Debt/Equity Ratio | 0% |
How did IMNM perform over the long term?
See historical performance and comparison